Omeros Corporation (OMER)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Omeros Corporation (OMER)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Omeros Corporation(“Omeros” or “the Company”) (NASDAQ: OMER). The investigation concerns whether Omeros and certain of its officers and/or directors have violated federal securities laws.
On November 4, 2019, Omeros issued a press release announcing the results of a prospective study of the Company’s ophthalmic drug Omidria. While the study results were positive, showing significantly less fentanyl use in cataract surgery patients receiving Omidria, the press release also advised investors that the Centers for Medicare and Medicaid Services (“CMS”) had not included Omidria in the non-opioid exclusion from packaged payment in CMS’s final rule related to its outpatient prospective payment system published on November 1, 2019. On this news, Omeros’s stock price fell sharply during intraday trading on November 4, 2019.
If you are aware of any facts relating to this investigation, or purchased Omeros shares,
you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.